Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 6
1969 5
1970 4
1971 5
1972 13
1973 8
1974 15
1975 20
1976 16
1977 4
1978 12
1979 9
1980 22
1981 11
1982 14
1983 15
1984 13
1985 12
1986 12
1987 25
1988 26
1989 27
1990 32
1991 22
1992 26
1993 25
1994 26
1995 21
1996 17
1997 20
1998 21
1999 20
2000 24
2001 25
2002 27
2003 32
2004 35
2005 41
2006 46
2007 39
2008 54
2009 34
2010 42
2011 35
2012 52
2013 41
2014 34
2015 38
2016 30
2017 26
2018 28
2019 23
2020 20
2021 34
2022 21
2023 30
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

1,248 results

Results by year

Filters applied: . Clear all
Page 1
Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub Typhus.
Varghese GM, Dayanand D, Gunasekaran K, Kundu D, Wyawahare M, Sharma N, Chaudhry D, Mahajan SK, Saravu K, Aruldhas BW, Mathew BS, Nair RG, Newbigging N, Mathew A, Abhilash KPP, Biswal M, Prasad AH, Zachariah A, Iyadurai R, Hansdak SG, Sathyendra S, Sudarsanam TD, Prakash JAJ, Manesh A, Mohan A, Tarning J, Blacksell SD, Peerawaranun P, Waithira N, Mukaka M, Cheah PY, Peter JV, Abraham OC, Day NPJ; INTREST Trial Investigators. Varghese GM, et al. N Engl J Med. 2023 Mar 2;388(9):792-803. doi: 10.1056/NEJMoa2208449. N Engl J Med. 2023. PMID: 36856615 Free PMC article. Clinical Trial.
METHODS: In this multicenter, double-blind, randomized, controlled trial, we compared the efficacy of intravenous doxycycline, azithromycin, or a combination of both in treating severe scrub typhus. ...No significant difference was seen between the azithromycin and doxy …
METHODS: In this multicenter, double-blind, randomized, controlled trial, we compared the efficacy of intravenous doxycycline, azithr …
Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L; ANRS IPERGAY Study Group. Molina JM, et al. Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8. Lancet Infect Dis. 2018. PMID: 29229440 Clinical Trial.
FINDINGS: Between July 20, 2015, and Jan 21, 2016, we randomly assigned 232 participants (n=116 in the doxycycline PEP group and n=116 in the no-PEP group) who were followed up for a median of 8.7 months (IQR 7.8-9.7). ...Gastrointestinal adverse events were reported in 62 …
FINDINGS: Between July 20, 2015, and Jan 21, 2016, we randomly assigned 232 participants (n=116 in the doxycycline PEP group and n=11 …
Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.
Stewart J, Oware K, Donnell D, Violette LR, Odoyo J, Soge OO, Scoville CW, Omollo V, Mogaka FO, Sesay FA, McClelland RS, Spinelli M, Gandhi M, Bukusi EA, Baeten JM; dPEP Kenya Study Team. Stewart J, et al. N Engl J Med. 2023 Dec 21;389(25):2331-2340. doi: 10.1056/NEJMoa2304007. N Engl J Med. 2023. PMID: 38118022 Clinical Trial.
No serious adverse events were considered by the trial investigators to be related to doxycycline, and there were no incident HIV infections. Among 50 randomly selected participants in the doxycycline-PEP group, doxycycline was detected in 58 of 200 hair samp …
No serious adverse events were considered by the trial investigators to be related to doxycycline, and there were no incident HIV inf …
Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease.
Rhodes JM, Subramanian S, Flanagan PK, Horgan GW, Martin K, Mansfield J, Parkes M, Hart A, Dallal H, Iqbal T, Butterworth J, Culshaw K, Probert C. Rhodes JM, et al. Dig Dis Sci. 2021 Aug;66(8):2700-2711. doi: 10.1007/s10620-020-06477-y. Epub 2020 Jul 17. Dig Dis Sci. 2021. PMID: 32681228 Clinical Trial.
METHODS: Adults with moderately active disease (CDAI > 220-450 plus C reactive protein 5 mg/l and/or fecal calprotectin > 250 mug/g) were randomized to receive (open-label) oral budesonide (Entocort CR 9 mg/day 8 weeks, 6 mg/day 2 weeks, 3 mg/day 2 weeks) or oral ciprofloxa …
METHODS: Adults with moderately active disease (CDAI > 220-450 plus C reactive protein 5 mg/l and/or fecal calprotectin > 250 mug/g) w …
A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease.
Allinson JP, Vlies BH, Brill SE, Law M, Burnside G, Finney LJ, Alves-Moreira L, Donaldson GC, Calverley PMA, Walker PP, Wedzicha JA. Allinson JP, et al. Am J Respir Crit Care Med. 2023 Sep 1;208(5):549-558. doi: 10.1164/rccm.202212-2287OC. Am J Respir Crit Care Med. 2023. PMID: 37450935 Free PMC article. Clinical Trial.

The COPD exacerbation rate did not differ between the groups (doxycycline/placebo rate ratio [RR], 0.86; 95% confidence interval [CI], 0.67-1.10; P = 0.23). ...George's Respiratory Questionnaire was 5.2 points worse in the doxycycline group at 12 months (P < 0.00

…
The COPD exacerbation rate did not differ between the groups (doxycycline/placebo rate ratio [RR], 0.86; 95% confidence interval [CI] …
Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial.
Majzoobi MM, Hashmi SH, Emami K, Soltanian AR. Majzoobi MM, et al. Infection. 2022 Oct;50(5):1267-1271. doi: 10.1007/s15010-022-01806-x. Epub 2022 Mar 30. Infection. 2022. PMID: 35353333 Free PMC article. Clinical Trial.
METHODS: In a single-blind randomized clinical trial, 92 patients with acute brucellosis were randomly divided in two treatment groups who received a triple drug regimen including doxycycline, streptomycin, and hydroxychloroquine (DSH] for 4 and 6 weeks. ...
METHODS: In a single-blind randomized clinical trial, 92 patients with acute brucellosis were randomly divided in two treatment groups who r …
COVID-19 prophylaxis with doxycycline and zinc in health care workers: a prospective, randomized, double-blind clinical trial.
Stambouli N, Driss A, Gargouri F, Bahrini K, Arfaoui B, Abid R, Taamallah K, Hannachi S, Boughariou S, Rebai A, Naas I, Ghanem M, Ammar H, Aichaouia C, Harrathi A, Yousfi MA, Battikh R, Moussa MB, Razgallah R, Ferjani M, Gharsallah H; of “OD-doxy-PNV-COVID-19 Trial”. Stambouli N, et al. Int J Infect Dis. 2022 Sep;122:553-558. doi: 10.1016/j.ijid.2022.06.016. Epub 2022 Jun 17. Int J Infect Dis. 2022. PMID: 35724828 Free PMC article. Clinical Trial.
OBJECTIVES: This study aims to assess the efficacy of a combination treatment of doxycycline and zinc in the primary prevention of COVID-19 infection in Tunisian health care workers compared with two control groups. METHODS: We conducted a prospective, randomized, double-b …
OBJECTIVES: This study aims to assess the efficacy of a combination treatment of doxycycline and zinc in the primary prevention of CO …
Efficacy of metformin vs. doxycycline in treating acne vulgaris: An assessor-blinded, add-on, randomized, controlled clinical trial.
Sadati MS, Yazdanpanah N, Shahriarirad R, Javaheri R, Parvizi MM. Sadati MS, et al. J Cosmet Dermatol. 2023 Oct;22(10):2816-2823. doi: 10.1111/jocd.15785. Epub 2023 May 2. J Cosmet Dermatol. 2023. PMID: 37128834 Clinical Trial.
For two months, the first group received doxycycline 100 mg capsules daily, and the second received metformin 500 mg tablets twice daily. ...RESULTS: By the end of the study, the GAGS, IGA, CADI, and TLC scores and the number of inflammatory and noninflammatory lesions dec …
For two months, the first group received doxycycline 100 mg capsules daily, and the second received metformin 500 mg tablets twice da …
Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN, Fu WJ, Wu Y, Dong YJ, Huang ZX, Wei YQ, Li CR, Sun CY, Chen Y, Miao HL, Zhang YL, Cao XX, Zhou DB, Li J. Shen KN, et al. Circulation. 2022 Jan 4;145(1):8-17. doi: 10.1161/CIRCULATIONAHA.121.055953. Epub 2021 Sep 10. Circulation. 2022. PMID: 34503349 Clinical Trial.
BACKGROUND: Doxycycline was demonstrated in a retrospective study to be associated with greater survival in patients with light chain amyloidosis. ...Patients with Mayo 2004 stage II to III light chain amyloidosis were included. Patients were randomized to doxycycline …
BACKGROUND: Doxycycline was demonstrated in a retrospective study to be associated with greater survival in patients with light chain …
Randomized control trial of prednisolone and doxycycline in patients with acute interstitial nephritis of unknown aetiology.
Badurdeen Z, Ratnatunga N, Abeysekera T, Wazil AWM, Rajakrishna PN, Thinnarachchi JP, Welagedera DD, Ratnayake N, Alwis APD, Abeysundara H, Kumarasiri R, Taylor R, Nanayakkara N. Badurdeen Z, et al. Trials. 2023 Jan 5;24(1):11. doi: 10.1186/s13063-022-07056-4. Trials. 2023. PMID: 36600250 Free PMC article. Clinical Trial.
BACKGROUND: Patients presenting with acute interstitial nephritis (AIN) of unknown aetiology, probably the earliest presentation of chronic kidney disease of unknown aetiology (CKDu), have been treated with oral prednisolone and doxycycline by physicians in Sri Lanka. This …
BACKGROUND: Patients presenting with acute interstitial nephritis (AIN) of unknown aetiology, probably the earliest presentation of chronic …
1,248 results